SCYNEXIS Stock

SCYNEXIS Equity

The The Equity of SCYNEXIS (SCYX) as of Sep 4, 2026 is 55.08 M USD. In the previous year, The Equity was 72.96 M USD — a change of -24.51% (lower).

Equity

55.08 MUSD

YoY

-24.51%

Last updated:

In 2026, SCYNEXIS's equity was 55.08 M USD, a -24.51% increase from the 72.96 M USD equity in the previous year.

The SCYNEXIS Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2017
21.40 M USD
Jan 1, 2018
31.20 M USD
Jan 1, 2019
12.90 M USD
Jan 1, 2020
22.80 M USD
Jan 1, 2021
41.30 M USD
Jan 1, 2022
3.20 M USD
Jan 1, 2023
72.96 M USD
Jan 1, 2024
55.08 M USD
The SCYNEXIS Equity history
YEAREquityYoY
55.08 MUSD-24.51%
72.96 MUSD+2,180.06%
3.20 MUSD-92.25%
41.30 MUSD+81.14%
22.80 MUSD+76.74%
12.90 MUSD-58.65%
31.20 MUSD+45.79%
21.40 MUSD-38.51%
34.80 MUSD-16.95%
41.90 MUSD+25.45%
33.40 MUSD
Access this data via the Eulerpool API

SCYNEXIS Stock analysis

What does SCYNEXIS do? SCYNEXIS Inc is a biopharmaceutical company that focuses on the discovery and development of novel therapeutics for serious infectious diseases and cancer. The company was founded in 2000 and is headquartered in New Jersey, USA. SCYNEXIS is one of the most popular companies on Eulerpool.

Equity Details

Analyzing SCYNEXIS's Equity

SCYNEXIS's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding SCYNEXIS's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating SCYNEXIS's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

SCYNEXIS's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in SCYNEXIS’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about SCYNEXIS stock

The Equity of SCYNEXIS is 55.08 M USD in 2026.

The Equity of SCYNEXIS changed from 72.96 M USD to 55.08 M USD, representing a -24.51% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity SCYNEXIS since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's SCYNEXIS historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — SCYNEXIS

All Key Metrics — SCYNEXIS